Best Peptides for Liver Health, NAFLD & MASH: Evidence (2026)
An evidence-first ranking of the peptide drugs studied for fatty liver disease (NAFLD/MASLD) and steatohepatitis (MASH) — anchored in biopsy-confirmed human RCTs, not marketing.
FDA Approved
FDA Approved is a recurring topic in our peptide coverage. This hub collects every article tagged FDA Approved, newest first, each evidence-graded and tied to real, verifiable sources.
Tirzepatide: Evidence, Mechanism, Dosing & Legal Status
A clinical monograph on tirzepatide — the dual GIP/GLP-1 co-agonist sold as Mounjaro and Zepbound. Grade-A RCT evidence for diabetes, obesity and sleep apnea, with a boxed warning and a tightening 2026 compounding landscape.
Tesamorelin: Evidence, Mechanism, Dosing & Legal Status
A clinical monograph on tesamorelin (Egrifta / EGRIFTA WR) — the FDA-approved GHRH analog with genuine Grade-A human RCT evidence for visceral fat in HIV lipodystrophy, and an unproven non-HIV anti-aging market.
Teriparatide: Evidence, Mechanism, Dosing & Legal Status
A clinical monograph on teriparatide — recombinant human PTH(1-34), the first bone-anabolic osteoporosis drug. Grade A RCT fracture data, a clear anabolic mechanism, and a 2026 status with no controlled-substance restrictions.
SS-31 (Elamipretide): Evidence, Mechanism & FDA Status
A clinical monograph on SS-31 / elamipretide (Forzinity) — the cardiolipin-binding, mitochondria-targeted tetrapeptide. First FDA-approved for Barth syndrome in 2025, yet negative on every other large trial's primary endpoint.
Orforglipron (Foundayo): Evidence, Mechanism & Status
A clinical monograph on orforglipron — the first oral, non-peptide small-molecule GLP-1 receptor agonist, FDA-approved as Foundayo in 2026 for chronic weight management, with Grade A Phase 3 RCT evidence.
Semaglutide: Evidence, Mechanism, Dosing & Legal Status
A clinical monograph on semaglutide — the long-acting GLP-1 receptor agonist behind Ozempic, Wegovy and Rybelsus. Grade-A human RCT evidence across diabetes, obesity, cardiovascular, kidney and liver disease.
PT-141 (Bremelanotide): Evidence, Mechanism & Legal Status
A clinical monograph on PT-141 (bremelanotide) — the centrally acting melanocortin agonist FDA-approved as Vyleesi for premenopausal HSDD. Grade-A human RCT data, a narrow label, and a real pressor and pigmentation safety profile.
Pramlintide (SYMLIN): Evidence, Mechanism & Legal Status
A clinical monograph on pramlintide — the synthetic amylin analog and only non-insulin mealtime adjunct FDA-approved for type 1 and type 2 diabetes, with Grade-A human RCT evidence and a boxed warning for severe hypoglycemia.
Pentosan Polysulfate: Evidence, Mechanism & Risks
A clinical monograph on pentosan polysulfate (Elmiron) — the FDA-approved interstitial-cystitis drug that is not a peptide, its off-label knee-osteoarthritis use, and its serious cumulative-dose eye risk.
Oxytocin: Evidence, Mechanism, Dosing & Legal Status
A clinical monograph on oxytocin — the posterior-pituitary nonapeptide that is an FDA-approved obstetric drug (Grade A) yet a largely failed intranasal 'bonding' peptide. Two drugs, two very different evidence bases.
Setmelanotide (Imcivree): Evidence, Mechanism & Legal Status
A clinical monograph on setmelanotide (Imcivree) — the MC4R-agonist octapeptide approved for rare genetic and hypothalamic obesity. Grade A human evidence in narrow indications, not a general weight-loss drug.
Melanotan I (Afamelanotide): Evidence, Mechanism & Legal Status
A clinical monograph on Melanotan I — INN afamelanotide, marketed as SCENESSE — the only FDA-approved melanocortin agonist, with Grade-A EPP photoprotection data and a separate unapproved gray-market tanning identity.
Lixisenatide: Evidence, Mechanism, Dosing & Legal Status
A clinical monograph on lixisenatide (Adlyxin/Lyxumia) — the short-acting, exendin-4-derived GLP-1 receptor agonist for type 2 diabetes, with a large RCT base, proven cardiovascular safety, and an emerging Parkinson's signal.
Liraglutide: Evidence, Mechanism, Dosing & Legal Status
A clinical monograph on liraglutide — the once-daily GLP-1 receptor agonist sold as Victoza and Saxenda. Grade A human RCT evidence for glycemic control, weight loss, and reduced cardiovascular death.
Exenatide in Pediatric Type 2 Diabetes: Evidence & Status
A clinical monograph on exenatide — the first-in-class GLP-1 receptor agonist (synthetic exendin-4) — with a focus on its Grade A pediatric type 2 diabetes evidence, mechanism, dosing from the literature, safety, and 2026 regulatory status.
Insulin: Evidence, Mechanism, Dosing & Legal Status
A clinical monograph on insulin — the prototype FDA-approved therapeutic peptide. Grade-A human evidence in diabetes, a tyrosine-kinase mechanism, and a stark warning on lethal non-medical 'anabolic' misuse.
Glucagon: Evidence, Mechanism, Dosing & Legal Status
A clinical monograph on glucagon — the 29-amino-acid pancreatic counter-regulatory hormone. FDA-approved since 1960 for severe-hypoglycemia rescue, graded A on decades of human RCTs, and now the glucagon-receptor arm of next-generation metabolic agonists.
Teduglutide (GLP-2): Evidence, Mechanism & Status
A clinical monograph on teduglutide — the GLP-2 receptor agonist FDA-approved for short bowel syndrome with intestinal failure. Grade A RCT evidence for SBS-IF, a mandated neoplasia-surveillance burden, and unproven 'leaky-gut' hype.
Dulaglutide: Evidence, Mechanism, Dosing & Legal Status
A clinical monograph on dulaglutide (Trulicity) — the once-weekly GLP-1-Fc fusion biologic with Grade A human RCT evidence for glycemic control and a 12% cardiovascular event reduction.
Frequently asked
What is FDA Approved?
FDA Approved is a topic our editors cover across the site. This hub aggregates the related, evidence-graded guidance.
How often is the FDA Approved hub updated?
This hub updates automatically whenever a new article is tagged FDA Approved, so the latest coverage appears first.
Are FDA Approved claims sourced?
Yes. Every article here grades its efficacy claims A-D and cites real, verifiable studies, regulatory documents or trial registries.